Mymetics Corp (MYMX)

[Work Harder]

From pg 16 placebo vaccine vp02 Catalent patent

Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors

Authors

Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA

Vector production and quantitation

ZVex/OVA vectors were designed and produced based on the VP02 platform previously described44. Briefly, vectors were produced via the transient transfection of 293T cells with 5 plasmids: the transfer vector that encodes the VP02 genome and ovalbumin, a modified gagpol transcript (RI-gagpol), accessory protein Rev from HIV-1, accessory protein Vpx from SIVmac, and the E1001 envelop glycoprotein variant of Sindbis virus.

https://www.nature.com/articles/s41541-020-0201-x

ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities

https://www.researchgate.net/publication/343768011_ZVex_a_dendritic-cell-tropic_lentivector_primes_protective_antitumor_T_cell_responses_that_are_significantly_boosted_using_heterologous_vaccine_modalities

ZVex

HIV-1 Conserved Mosaics Delivered by Regimens
with Integration-Deficient DC-Targeting Lentiviral
Vector Induce Robust T Cell

https://www.cell.com/molecular-therapy-family/molecular-therapy/pdfExtended/S1525-0016(16)45421-3

VP02, of the ZVex platform

https://www.pubfacts.com/detail/26942209/Design-of-a-titering-assay-for-lentiviral-vectors-utilizing-direct-extraction-of-DNA-from-transduced

Immune Design , Seattle, Washington, USA.

& I'm sure there is more